Forward Pharma A/S Announces Termination of its American Depositary Receipts (“ADR”) Facility

Rhea-AI Summary

Forward Pharma A/S (Forward) announced the termination of the Deposit Agreement, dated October 14, 2014, resulting in the termination of the existing ADR facility effective February 5, 2024.

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Forward Pharma A/S (“Forward” or the “Company”) today announced that its Board of Directors has approved a termination of the Deposit Agreement, dated October 14, 2014, among Forward Pharma A/S (Forward Pharma), the Depositary Bank of New York Mellon, and Owners and Holders of ADRs.

As a result, the existing ADR facility will be terminated effective at 5:00 PM (Eastern Time) on February 5, 2024.

Kindly see additional information at the website of the Depositary Bank of New York Mellon (https://www.adrbnymellon.com/files/ad1136444.pdf).

Forward Pharma A/S Investor Relations Contact:
Investor Relations
investors@forward-pharma.com

FAQ

What did Forward Pharma A/S announce?

Forward Pharma A/S announced the termination of the Deposit Agreement, resulting in the termination of the existing ADR facility effective February 5, 2024.

When will the termination be effective?

The termination of the existing ADR facility will be effective at 5:00 PM (Eastern Time) on February 5, 2024.

Where can additional information be found?

Additional information can be found at the website of the Depositary Bank of New York Mellon (https://www.adrbnymellon.com/files/ad1136444.pdf).